New Drug Approvals

Home » Uncategorized » Divalproex sodium

Divalproex sodium

DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO .....FOR BLOG HOME CLICK HERE

ORGANIC SPECTROSCOPY

Read all about Organic Spectroscopy on ORGANIC SPECTROSCOPY INTERNATIONAL 

Categories

Recent Posts

Blog Stats

  • 3,719,561 hits

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 2,674 other followers

add to any

Share

Divalproex sodium.png
Divalproex Sodium | ≥99%(HPLC) | Selleck | HDAC inhibitor

 Divalproex

  • 44089

WeightAverage: 144.2114
Chemical FormulaC8H16O2

UNII614OI1Z5WI, CAS number99-66-1, 76584-70-8

2-propylpentanoic acid, DIVALPROEX SODIUM76584-70-8Valproate semisodiumEpivalDepakoteSodium divalproateSemisodium ValproateAbbott 50711ValdisovalValproic Acid 
CAS Registry Number: 99-66-1 
CAS Name: 2-Propylpentanoic acid 
Additional Names: 2-propylvaleric acid; di-n-propylacetic acid 
Trademarks: Convulex (Pharmacia); Depakene (Abbott) 
Molecular Formula: C8H16O2 
Molecular Weight: 144.21 
Percent Composition: C 66.63%, H 11.18%, O 22.19% 
Literature References: Antiepileptic; increases levels of g-aminobutyric acid (GABA) in the brain. Prepn: B. S. Burton, Am. Chem. J.3, 385 (1882); E. Oberreit, Ber.29, 1998 (1896); M. Tiffeneau, Y. Deux, Compte Rend.212, 105 (1941). Anticonvulsant activity: H. Meunier et al.,Therapie18, 435 (1963). Toxicity data: Jenner et al.,Food Cosmet. Toxicol.2, 327 (1964). Comprehensive description: Z. L. Chang, Anal. Profiles Drug Subs.8, 529-556 (1979). Review of teratogenicity studies: H. Nau et al.,Pharmacol. Toxicol.69, 310-321 (1991); R. Alsdorf, D. F. Wyszynski, Expert Opin. Drug Safety4, 345-353 (2005). Review of pharmacology and clinical experience in epilepsy: E. M. Rimmer, A. Richens, Pharmacotherapy5, 171-184 (1985); in psychiatric disease: D. R. P. Guay, ibid.15, 631-647 (1995); in migraine prophylaxis: C. E. Shelton, J. F. Connelly, Ann. Pharmacother.30, 865-866 (1996). Review of pharmacodynamics and mechanisms of action: W. Löscher, Prog. Neurobiol.58, 31-59 (1999). 
Properties: Colorless liquid with characteristic odor. bp 219.5°. nD24.5 1.425. d40 0.9215. pKa 4.6. Very sol in organic solvents. Soly in water: 1.3 mg/ml. LD50 orally in rats: 670 mg/kg (Jenner). 
Boiling point: bp 219.5° 
pKa: pKa 4.6 
Index of refraction:nD24.5 1.425 
Density: d40 0.9215 
Toxicity data: LD50 orally in rats: 670 mg/kg (Jenner) 
Derivative Type: Sodium salt (1:1) 
CAS Registry Number: 1069-66-5 
Additional Names: Sodium valproate 
Trademarks: Depacon (Abbott); Depakin (Sanofi-Synthelabo); Dépakine (Sanofi-Aventis); Epilim (Sanofi-Aventis); Ergenyl (Sanofi-Synthelabo); Leptilan (Dolorgiet); Orfiril (Desitin) 
Molecular Formula: C8H15NaO2 
Molecular Weight: 166.19 
Percent Composition: C 57.82%, H 9.10%, Na 13.83%, O 19.25% 
Properties: White, odorless, crystalline, deliquescent powder. pKa 4.8. Hygroscopic. One gram is sol in 0.4 ml water; 1.5 ml ethanol; 5 ml methanol. Practically insol in common organic solvents. LD50 orally in mice: 1700 mg/kg (Meunier). 
pKa: pKa 4.8 
Toxicity data: LD50 orally in mice: 1700 mg/kg (Meunier) 
Derivative Type: Sodium salt (2:1) 
CAS Registry Number: 76584-70-8 
Additional Names: Sodium hydrogen bis(2-propylpentanoate); divalproex sodium; valproate semisodium 
Manufacturers’ Codes: Abbott 50711 
Trademarks: Depakote (Abbott); Valcote (Abbott) 
Molecular Formula: C16H31NaO4 
Molecular Weight: 310.40 
Percent Composition: C 61.91%, H 10.07%, Na 7.41%, O 20.62% 
Derivative Type: Magnesium salt 
Trademarks: Depamag (Sigma-Tau) 
Molecular Formula: C16H30MgO4 
Molecular Weight: 310.71 
Percent Composition: C 61.85%, H 9.73%, Mg 7.82%, O 20.60% 
Therap-Cat: Anticonvulsant; antimanic; antimigraine.Keywords: Anticonvulsant; Antimigraine; Antimanic.

Synthesis Reference

Daniel Aubert, Francis Blanc, Henri Desmolin, Michel Morre, Lucette Sindely, “Valproic acid preparations.” U.S. Patent US5017613, issued January, 1965.

US5017613

Patent

https://patents.google.com/patent/WO2007004238A2/enDivalproex sodium is one of the most widely used epileptic agents presently available in the market. Both the constituents, valproic acid and sodium valproate themselves have also been used for the treatment of epileptic seizures and convulsions. But their utility has remained restricted since valproic acid is a liquid and is difficult to formulate for an oral dosage form whereas sodium valproate is a hygroscopic solid with poor stability characteristics. Divalproex sodium is an oligomer having 1:1 molar ratio of valproic acid and sodium valproate containing 4 to 6 units. The relevant prior art includes US 4,988,731 (’73I) relates to a non-hygroscopic stable sodium hydrogen divalproate oligomer. Its probable structure is shown in Fig 1

Figure imgf000002_0001

Fig 1 – Divalproex sodiumWhere M is a about 2.As can be seen from the displayed structure, one mole each of the valproic acid forms coordinate bonds with the sodium of the sodium valproate molecule, and the valproate ion is ionically bonded to the sodium atom. The structure is thus consistent with the unique characteristic of the compound. However the preferred mode of representing Divalproex sodium is by reference to single compound of the formula{(CH3CH2CH2)2CHCO2} {(CH3CH2CH2)2CHCO2}Na, HThe said patent also describes two alternative processes for the preparation of the oligomer. According to one aspect, the oligomer is produced by dissolving sodium valproate and valproic acid in equimolar amount in acetone and crystallizing from chilled acetone at around O0C. Alternatively Divalproex sodium can be isolated from a two component liquid medium, which includes acetone where in half equivalent of NaOH to the valproic acid present, preferable as a solution in an acetone miscible solvent eg. water. The new compound can be recovered from the liquid phase by evaporating the solvent(s) and, if desired, the new compound can be recrystallized, for instance from acetonitrile or others or the material may be spay-dried, lyophilized or purified by chromatography.US ‘731 claims yield of 90% of theory.Drawbacks of the above mentioned reported methods for the preparation of Divalproex sodium described in US 4988731 are difficult to reproduce on a large scale and provides inconsistent yields and the material obtained is not always free flowing in nature. The process involves the crystallization of a 1:1 mixture of valproic acid and sodium valproate from a chilled solution of acetone, followed by washing with chilled acetone. Divalproex sodium is as such fairly soluble in acetone at temperatures above 1O0C and extreme care has to be. taken while performing washing with chilled acetone as any rise in temperature would lead to the loss of yield. This problem actually comes to the fore while scaling up the process during commercialization since during centrifugation of the large volume the temperature of the mixture rises and acetone has to be cooled below O0C, which require large amount of liquid nitrogen or dry ice. Moreover it was also observed that due to the cooled nature of the solvent, the isolated Divalproex sodium absorbs considerable amount of moisture and therefore requires longer time to dry eventually leading to longer time cycle for the otherwise simple single step process. Also the high moisture content in the recovered acetone makes it unsuitable for reuse. Alternatively, to avoid absorption of water, the centrifugation had to be carried out under a blanket of dry nitrogen gas. These additional infrastructural loads add to input costs eventually making the otherwise single step low cost process becoming uncompetitive and economically unviable.Similarly the other process involves the addition of half molar equivalent of sodium hydroxide dissolved in water to valproic acid and the solvent has to be evaporated to obtain crude product, which has to be recrystallized to get Divalprox of the desired specification. The process is operationally tedious and requires the reduction in the level of water in the reaction mass via evaporation of the solvent followed by re- crystallization from acetonitrile making the process lengthy and economically unviable. There is therefore a need for operationally making this single step process more efficient and high yieldingExample I:To lOOg of Valproic acid with stirring at 20-300C, powdered NaOH ( 13g; half molar) is added & the resulting reaction mixture is stirred at 40-500C for 1 hr. Then acetonitrile(600ml) is added to obtain clear solution at 40-500C and the solution is charcoalized at 40-500C followed by filtration at 40-500C through hyflo-bed. The resultant reaction mixture was stirred at 10-200C for 2-3 hr. The solid , thus obtained, was filtered and product was dried at 40-450C for 10-12 hr. (102.25g, 95%)Example II;To lOOg of Valproic acid with stirring at 20-300C, powdered NaOH (13g; half molar) is added & the resulting reaction mixture is stirred at 30-400C for 1 hr. Then acetone (600ml) is added to obtain clear solution at 30-400C and the material is charcoalized at 30-400C followed by filtration through hyflo-bed. The resultant reaction solution was stirred at -5°C to -1O0C for 2-3 hr. The solid , thus obtained, was filtered and product was dried at 40-450C for 10-12 hr. ( 55g, 51.11%) Example III:To a solution of Valproic acid (10Og) in dichloromethane (200ml) at 20-300C, powdered caustic (13g ; half molar) is added & the reaction mixture is stirred at 30- 400C for 1 hr to get clear solution. Then acetonitrile (600ml) is added to it inorder to crystallize the product. The solid, thus obtained, is further stirred at 0-50C for 2-3 hr followed by filtration. The product was dried at 40-450C for 10-12 hr. (10Og; 93%)Example IV:To a solution of Valproic acid (10Og) in diisopropyl ether(200ml) at 20-300C, powdered caustic (13g ; half molar) is added & the reaction mixture is stirred at 40-500C for 1 hr to get clear solution. Then acetonitrile (800ml) is added to it inorder to crystallize the product. The solid, thus obtained, is further stirred at 0-50C for 2-3 hr followed by filtration. The product was dried at 40-450C for 10-12 hr. (104g; 96.65%)Example V:To a solution of Valproic acid (10Og) in methyl tertiary butyl ether(200ml) at 20- 300C, powdered caustic (13g ; half molar) is added & the reaction mixture is stirred at 40-500C for 1 hr to get clear solution. Then acetonitrile (800ml) is added to it inorder to crystallize the product. The solid, thus obtained, is further stirred at 0-50C for 2-3 hr followed by filtration. The product was dried at 40-450C for 10-12 hr. (102g;94.79%)Example VI:To a solution of Valproic acid (10Og) in toluene (200ml) at 20-300C, powdered caustic (13g ; half molar) is added & the reaction mixture is stirred at 40-500C for 1 hr to get clear solution. Then acetonitrile (800ml) is added to it inorder to crystallize the product. The solid, thus obtained, is further stirred at 0-50C for 2-3 hr followed by filtration. The product was dried at 40-450C for 10-12 hr. (101g; 93.87%)Example VII: A mixture of sodium valproate (6Og) and valproic acid (52.04g) was taken in acetonitrile (800ml) and heated at reflux to obtain a clear solution, which was filtered through hyflo-bed to remove suspended particles. Then the solution was stirred at 10- 200C for 2-3 hr. The solid, thus obtained, was filtered and washed with acetonitrile (100ml). The product was dried at 40-450C for 10-12 hr. (105g ; 93.75%)Example VIII;To a solution of valproic acid (10Og) in methanol (200ml) at 20-300C5 caustic (13g; half molar) is added & the reaction mixture is stirred at 20-300C for 1 hr. Then the methanol was recovered at reduced pressure and acetonitrile (600ml) is added to it with stirring. The reaction mixture was further stirred at 0-50C for 2-3 hr. The solid, thus obtained, is filtered, washed with acetonitrile (100ml) and product was dried at 40-45°C for 10-12 hr.(102g; ~ 95%) Example IX:To a solution of valproic acid (10Og) in methanol (200ml) at 20-300C, caustic (13g; half molar) is added & the reaction mixture is stirred at 20-300C for 1 hr. Then the methanol was recovered at reduced pressure and acetone (600ml) is added to it with stirring. The reaction mixture was further stirred at -5°C to -1O0C for 2-3 hr. The solid, thus obtained, is filtered, washed with chilled acetone (100ml) and product was dried at 40-450C for 10-12 hr.(54g; ~ 50.11%)Example X:To a solution of valproic acid (10Og) in ethanol (200ml) at 20-300C, caustic (13g; half molar) is added & the reaction mixture is stirred at 20-300C for 1 hr. Then the ethanol was recovered at reduced pressure and acetonitrile (600ml) is added to it with stirring.The reaction mixture was further stirred at 0-50C for 2-3 hr. The solid, thus obtained, is filtered, washed with acetonitrile (100ml) and product was dried at 40-450C for 10-12 hr.(101g; ~ 93.87%)Example XI: To a solution of valproic acid (10Og) in ethanol (200ml) at 20-30°C, caustic (13g; half molar) is added & the reaction mixture is stirred at 20-300C for 1 hr. Then the ethanol was recovered at reduced pressure and acetone (600ml) is added to it with stirring. The reaction mixture was further stirred at -5°C to -100C for 2-3 hr. The solid, thus obtained, is filtered, washed with chilled acetone (100ml) and product was dried at 40-450C for 10-12 hr.(55g; ~ 51%)ADVANTAGES:> The process is high yielding. > The process produces Divalproex sodium with improved flowability.> The process produces Divalproex sodium that is non-hygroscopic and more stable.> The process is industrially feasible, precise, reproducible and does not require sophisticated infrastructure.

Divalproex Sodium is a stable coordination compound comprised of sodium valproate and valproic acid with anticonvulsant and antiepileptic activities. Divalproex dissociates to the valproate ion in the gastrointestinal tract. This agent binds to and inhibits gamma-aminobutyric acid (GABA) transaminase and its anticonvulsant activity may be exerted by increasing brain concentration of GABA and by inhibiting enzymes that catabolize GABA or block the reuptake of GABA into glia and nerve endings. Divalproex may also work by suppressing repetitive neuronal firing through inhibition of voltage-sensitive sodium channels.

Valproate semisodium is a mixture of valproic acid and its sodium salt in a 1:1 molar ratio. It is used for the management and treatment of seizure disorders, mania, and prophylactic treatment of migraine headache. It has a role as an antimanic drug, an anticonvulsant and a GABA agent. It contains a valproic acid and a sodium valproate.

Divalproex sodium, valproate sodium, and valproic acid, are all similar medications that are used by the body as valproic acid. Therefore, the term valproic acid will be used to represent all of these medications in this discussion.

Valproate (VPA) and its valproic acidsodium valproate, and valproate semisodium forms are medications primarily used to treat epilepsy and bipolar disorder and prevent migraine headaches.[2] They are useful for the prevention of seizures in those with absence seizurespartial seizures, and generalized seizures.[2] They can be given intravenously or by mouth, and the tablet forms exist in both long- and short-acting formulations.[2]

Common side effects of valproate include nausea, vomiting, sleepiness, and dry mouth.[2] Serious side effects can include liver failure, and regular monitoring of liver function tests is therefore recommended.[2] Other serious risks include pancreatitis and an increased suicide risk.[2] Valproate is known to cause serious abnormalities in babies if taken during pregnancy,[2][3] and as such it is not typically recommended for women of childbearing age who have migraines.[2]

Valproate’s precise mechanism of action is unclear.[2][4] Proposed mechanisms include affecting GABA levels, blocking voltage-gated sodium channels, and inhibiting histone deacetylases.[5][6] Valproic acid is a branched short-chain fatty acid (SCFA) made from valeric acid.[5]

Valproate was first made in 1881 and came into medical use in 1962.[7] It is on the World Health Organization’s List of Essential Medicines[8] and is available as a generic medication.[2] It is marketed under the brand names Depakote, among others.[2] In 2018, it was the 131st most commonly prescribed medication in the United States, with more than 5 million prescriptions.[9][10]

Terminology

Valproic acid (VPA) is an organic weak acid. The conjugate base is valproate. The sodium salt of the acid is sodium valproate and a coordination complex of the two is known as valproate semisodium.[11]

Medical uses

It is used primarily to treat epilepsy and bipolar disorder. It is also used to prevent migraine headaches.[12]

Epilepsy

Valproate has a broad spectrum of anticonvulsant activity, although it is primarily used as a first-line treatment for tonic–clonic seizuresabsence seizures and myoclonic seizures and as a second-line treatment for partial seizures and infantile spasms.[12][13] It has also been successfully given intravenously to treat status epilepticus.[14][15]

Mental illness

Bipolar disorder

Valproate products are also used to treat manic or mixed episodes of bipolar disorder.[16][17]

Schizophrenia

A 2016 systematic review compared the efficacy of valproate as an add-on for people with schizophrenia:[18]

There is limited evidence that adding valproate to antipsychotics may be effective for overall response and also for specific symptoms, especially in terms of excitement and aggression. Valproate was associated with a number of adverse events among which sedation and dizziness appeared more frequently than in the control groups.[18]
showOutcomeFindings in wordsFindings in numbersQuality of evidence

Dopamine dysregulation syndrome

Based upon five case reports, valproic acid may have efficacy in controlling the symptoms of the dopamine dysregulation syndrome that arise from the treatment of Parkinson’s disease with levodopa.[19][20][21]

Migraines

Valproate is also used to prevent migraine headaches. Because this medication can be potentially harmful to the fetus, valproate should be considered for those able to become pregnant only after the risks have been discussed.[22]

Other

The medication has been tested in the treatment of AIDS and cancer, owing to its histone-deacetylase-inhibiting effects.[23]

Contraindications

Contraindications include:

Adverse effects

See also: List of adverse effects of valproic acid and List of adverse effects of valproate semisodium

Most common adverse effects include:[22]

Serious adverse effects include:[22]

Valproic acid has a black box warning for hepatotoxicitypancreatitis, and fetal abnormalities.[22]

There is evidence that valproic acid may cause premature growth plate ossification in children and adolescents, resulting in decreased height.[26][27][28][29] Valproic acid can also cause mydriasis, a dilation of the pupils.[30] There is evidence that shows valproic acid may increase the chance of polycystic ovary syndrome (PCOS) in women with epilepsy or bipolar disorder. Studies have shown this risk of PCOS is higher in women with epilepsy compared to those with bipolar disorder.[31] Weight gain is also possible.[32]

Pregnancy

Valproate causes birth defects;[33] exposure during pregnancy is associated with about three times as many major abnormalities as usual, mainly spina bifida with the risks being related to the strength of medication used and use of more than one drug.[34][35] More rarely, with several other defects, including a “valproate syndrome”.[36] Characteristics of this valproate syndrome include facial features that tend to evolve with age, including a triangle-shaped forehead, tall forehead with bifrontal narrowing, epicanthic folds, medial deficiency of eyebrows, flat nasal bridge, broad nasal root, anteverted nares, shallow philtrum, long upper lip and thin vermillion borders, thick lower lip and small downturned mouth.[37] While developmental delay is usually associated with altered physical characteristics (dysmorphic features), this is not always the case.[38]

Children of mothers taking valproate during pregnancy are at risk for lower IQs.[39][40][41] Maternal valproate use during pregnancy increased the probability of autism in the offspring compared to mothers not taking valproate from 1.5% to 4.4%.[42] A 2005 study found rates of autism among children exposed to sodium valproate before birth in the cohort studied were 8.9%.[43] The normal incidence for autism in the general population is estimated at less than one percent.[44] A 2009 study found that the 3-year-old children of pregnant women taking valproate had an IQ nine points lower than that of a well-matched control group. However, further research in older children and adults is needed.[45][46][47]

Sodium valproate has been associated with paroxysmal tonic upgaze of childhood, also known as Ouvrier–Billson syndrome, from childhood or fetal exposure. This condition resolved after discontinuing valproate therapy.[48][49]

Women who intend to become pregnant should switch to a different medication if possible or decrease their dose of valproate.[50] Women who become pregnant while taking valproate should be warned that it causes birth defects and cognitive impairment in the newborn, especially at high doses (although valproate is sometimes the only drug that can control seizures, and seizures in pregnancy could have worse outcomes for the fetus than exposure to valproate). Studies have shown that taking folic acid supplements can reduce the risk of congenital neural tube defects.[22] The use of valproate for migraine or bipolar disorder during pregnancy is contraindicated in the European Union, and the medicines are not recommended for epilepsy during pregnancy unless there is no other effective treatment available.[51]

Elderly

Valproate in elderly people with dementia caused increased sleepiness. More people stopped the medication for this reason. Additional side effects of weight loss and decreased food intake were also associated with one-half of people who become sleepy.[22]

Overdose and toxicity

FormLower limitUpper limitUnit
Total (including
protein bound)
50[52]125[52]µg/mL or mg/l
350[53]700[53]μmol/L
Free6[52]22[52]µg/mL or mg/l
35[53]70[53]μmol/L

Excessive amounts of valproic acid can result in sleepiness, tremorstuporrespiratory depressioncomametabolic acidosis, and death.[54] In general, serum or plasma valproic acid concentrations are in a range of 20–100 mg/l during controlled therapy, but may reach 150–1500 mg/l following acute poisoning. Monitoring of the serum level is often accomplished using commercial immunoassay techniques, although some laboratories employ gas or liquid chromatography.[55] In contrast to other antiepileptic drugs, at present there is little favorable evidence for salivary therapeutic drug monitoring. Salivary levels of valproic acid correlate poorly with serum levels, partly due to valproate’s weak acid property (pKa of 4.9).[56]

In severe intoxication, hemoperfusion or hemofiltration can be an effective means of hastening elimination of the drug from the body.[57][58] Supportive therapy should be given to all patients experiencing an overdose and urine output should be monitored.[22] Supplemental L-carnitine is indicated in patients having an acute overdose[59][60] and also prophylactically[59] in high risk patients. Acetyl-L-carnitine lowers hyperammonemia less markedly[61] than L-carnitine.

Interactions

Valproate inhibits CYP2C9glucuronyl transferase, and epoxide hydrolase and is highly protein bound and hence may interact with drugs that are substrates for any of these enzymes or are highly protein bound themselves.[24] It may also potentiate the CNS depressant effects of alcohol.[24] It should not be given in conjunction with other antiepileptics due to the potential for reduced clearance of other antiepileptics (including carbamazepinelamotriginephenytoin and phenobarbitone) and itself.[24] It may also interact with:[22][24][62]

  • Aspirin: may increase valproate concentrations. May also interfere with valproate’s metabolism.
  • Benzodiazepines: may cause CNS depression and there are possible pharmacokinetic interactions.
  • Carbapenem antibiotics: reduce valproate levels, potentially leading to seizures.
  • Cimetidine: inhibits valproate’s metabolism in the liver, leading to increased valproate concentrations.
  • Erythromycin: inhibits valproate’s metabolism in the liver, leading to increased valproate concentrations.
  • Ethosuximide: valproate may increase ethosuximide concentrations and lead to toxicity.
  • Felbamate: may increase plasma concentrations of valproate.
  • Mefloquine: may increase valproate metabolism combined with the direct epileptogenic effects of mefloquine.
  • Oral contraceptives: may reduce plasma concentrations of valproate.
  • Primidone: may accelerate metabolism of valproate, leading to a decline of serum levels and potential breakthrough seizure.
  • Rifampicin: increases the clearance of valproate, leading to decreased valproate concentrations
  • Warfarin: valproate may increase free warfarin concentration and prolong bleeding time.
  • Zidovudine: valproate may increase zidovudine serum concentration and lead to toxicity.

Pharmacology

Pharmacodynamics

Although the mechanism of action of valproate is not fully understood,[24] traditionally, its anticonvulsant effect has been attributed to the blockade of voltage-gated sodium channels and increased brain levels of gamma-aminobutyric acid (GABA).[24] The GABAergic effect is also believed to contribute towards the anti-manic properties of valproate.[24] In animals, sodium valproate raises cerebral and cerebellar levels of the inhibitory synaptic neurotransmitter, GABA, possibly by inhibiting GABA degradative enzymes, such as GABA transaminasesuccinate-semialdehyde dehydrogenase and by inhibiting the re-uptake of GABA by neuronal cells.[24]

Prevention of neurotransmitter-induced hyperexcitability of nerve cells, via Kv7.2 channel and AKAP5, may also contribute to its mechanism.[63] Also, it has been shown to protect against a seizure-induced reduction in phosphatidylinositol (3,4,5)-trisphosphate (PIP3) as a potential therapeutic mechanism.[64]

It also has histone-deacetylase-inhibiting effects. The inhibition of histone deacetylase, by promoting more transcriptionally active chromatin structures, likely presents the epigenetic mechanism for regulation of many of the neuroprotective effects attributed to valproic acid. Intermediate molecules mediating these effects include VEGFBDNF, and GDNF.[65][66]

Endocrine actions

Valproic acid has been found to be an antagonist of the androgen and progesterone receptors, and hence as a nonsteroidal antiandrogen and antiprogestogen, at concentrations much lower than therapeutic serum levels.[67] In addition, the drug has been identified as a potent aromatase inhibitor, and suppresses estrogen concentrations.[68] These actions are likely to be involved in the reproductive endocrine disturbances seen with valproic acid treatment.[67][68]

Valproic acid has been found to directly stimulate androgen biosynthesis in the gonads via inhibition of histone deacetylases and has been associated with hyperandrogenism in women and increased 4-androstenedione levels in men.[69][70] High rates of polycystic ovary syndrome and menstrual disorders have also been observed in women treated with valproic acid.[70]

Pharmacokinetics

Some metabolites of valproic acid. Glucuronidation and β-oxidation are the main metabolic pathways; ω-oxidation metabolites are considered hepatotoxic.[71][72] Details see text.

Taken by mouth, valproate is rapidly and virtually completely absorbed from the gut.[71] When in the bloodstream, 80–90% of the substance are bound to plasma proteins, mainly albumin. Protein binding is saturable: it decreases with increasing valproate concentration, low albumin concentrations, the patient’s age, additional use of other drugs such as aspirin, as well as liver and kidney impairment.[73][74] Concentrations in the cerebrospinal fluid and in breast milk are 1 to 10% of blood plasma concentrations.[71]

The vast majority of valproate metabolism occurs in the liver.[75] Valproate is known to be metabolized by the cytochrome P450 enzymes CYP2A6CYP2B6CYP2C9, and CYP3A5.[75] It is also known to be metabolized by the UDP-glucuronosyltransferase enzymes UGT1A3UGT1A4UGT1A6UGT1A8UGT1A9UGT1A10UGT2B7, and UGT2B15.[75] Some of the known metabolites of valproate by these enzymes and uncharacterized enzymes include (see image):[75]

  • via glucuronidation (30–50%): valproic acid β-O-glucuronide
  • via beta oxidation (>40%): 2E-ene-valproic acid, 2Z-ene-valproic acid, 3-hydroxyvalproic acid, 3-oxovalproic acid
  • via omega oxidation: 5-hydroxyvalproic acid, 2-propyl-glutaric acid
  • some others: 3E-ene-valproic acid, 3Z-ene-valproic acid, 4-ene-valproic acid, 4-hydroxyvalproic acid

All in all, over 20 metabolites are known.[71]

In adult patients taking valproate alone, 30–50% of an administered dose is excreted in urine as the glucuronide conjugate.[75] The other major pathway in the metabolism of valproate is mitochondrial beta oxidation, which typically accounts for over 40% of an administered dose.[75] Typically, less than 20% of an administered dose is eliminated by other oxidative mechanisms.[75] Less than 3% of an administered dose of valproate is excreted unchanged (i.e., as valproate) in urine.[75] Only a small amount is excreted via the faeces.[71] Elimination half-life is 16±3 hours and can decrease to 4–9 hours when combined with enzyme inducers.[71][74]

Chemistry

Valproic acid is a branched short-chain fatty acid and the 2-npropyl derivative of valeric acid.[5]

History

Valproic acid was first synthesized in 1882 by Beverly S. Burton as an analogue of valeric acid, found naturally in valerian.[76] Valproic acid is a carboxylic acid, a clear liquid at room temperature. For many decades, its only use was in laboratories as a “metabolically inert” solvent for organic compounds. In 1962, the French researcher Pierre Eymard serendipitously discovered the anticonvulsant properties of valproic acid while using it as a vehicle for a number of other compounds that were being screened for antiseizure activity. He found it prevented pentylenetetrazol-induced convulsions in laboratory rats.[77] It was approved as an antiepileptic drug in 1967 in France and has become the most widely prescribed antiepileptic drug worldwide.[78] Valproic acid has also been used for migraine prophylaxis and bipolar disorder.[79]

Society and culture

Valproate is available as a generic medication.[2]

Approval status

Indications
FDA-labelled indication?[1]

TGA-labelled indication?[12]

MHRA-labelled indication?[80]
Literature support
EpilepsyYesYesYesLimited (depends on the seizure type; it can help with certain kinds of seizures: drug-resistant epilepsy, partial and absence seizures, can be used against glioblastoma and other tumors both to improve survival and treat seizures, and against tonic–clonic seizures and status epilepticus).[81][82][83][84]
Bipolar maniaYesYesYesLimited.[85]
Bipolar depressionNoNoNoModerate.[86]
Bipolar maintenanceNoNoNoLimited.[87]
Migraine prophylaxisYesYes (accepted)NoLimited.
Acute migraine managementNoNoNoOnly negative results.[88]
SchizophreniaNoNoNoWeak evidence.[89]
Agitation in dementiaNoNoNoWeak evidence. Not recommended for agitation in people with dementia.[90] Increased rate of adverse effects, including a risk of serious adverse effects.[90]
Fragile X syndromeYes (orphan)NoNoLimited.[66]
Familial adenomatous polyposisYes (orphan)NoNoLimited.
Chronic pain & fibromyalgiaNoNoNoLimited.[91]
Alcohol hallucinosisNoNoNoOne randomised double-blind placebo-controlled trial.[92]
Intractable hiccupsNoNoNoLimited, five case reports support its efficacy, however.[93]
Non-epileptic myoclonusNoNoNoLimited, three case reports support its efficacy, however.[94]
Cluster headachesNoNoNoLimited, two case reports support its efficacy.[95]
West syndromeNoNoNoA prospective clinical trial supported its efficacy in treating infantile spasms.[96]
HIV infection eradicationNoNoNoDouble-blind placebo-controlled trials have been negative.[97][98][99]
Myelodysplastic syndromeNoNoNoSeveral clinical trials have confirmed its efficacy as a monotherapy,[100] as an adjunct to tretinoin[100] and as an adjunct to hydralazine.[101]
Acute myeloid leukaemiaNoNoNoTwo clinical trials have confirmed its efficacy in this indication as both a monotherapy and as an adjunct to tretinoin.[102][103][104]
Cervical cancerNoNoNoOne clinical trial supports its use here.[105]
Malignant melanomaNoNoNoOne phase II study has seemed to discount its efficacy.[106]
Breast cancerNoNoNoA phase II study has supported its efficacy.[107]
Impulse control disorderNoNoNoLimited.[108][109]

Off-label uses

In 2012, pharmaceutical company Abbott paid $1.6 billion in fines to US federal and state governments for illegal promotion of off-label uses for Depakote, including the sedation of elderly nursing home residents.[110][111]

Some studies have suggested that valproate may reopen the critical period for learning absolute pitch and possibly other skills such as language.[112][113]

wdt-16

join me on Linkedin

Anthony Melvin Crasto Ph.D – India | LinkedIn

join me on Researchgate

RESEARCHGATE

This image has an empty alt attribute; its file name is research.jpg

join me on Facebook

Anthony Melvin Crasto Dr. | Facebook

join me on twitter

Anthony Melvin Crasto Dr. | twitter

+919321316780 call whatsaapp

EMAIL. amcrasto@amcrasto

/////////////////////////////////////////////////////////////////////////////////////////////////////

Formulations

Clinical data
Other namesvalproate sodium (USAN US)
License dataUS DailyMedValproate_sodium
Identifiers
showIUPAC name
CAS Number1069-66-5 
PubChem CID16760703
DrugBankDBSALT001257 
ChemSpider13428 
UNII5VOM6GYJ0D
KEGGD00710 
ChEBICHEBI:9925 
ChEMBLChEMBL433 
CompTox Dashboard (EPA)DTXSID6023733 
ECHA InfoCard100.002.525 
Chemical and physical data
FormulaC8H15NaO2
Molar mass166.196 g·mol−1
3D model (JSmol)Interactive image
showSMILES
showInChI
  (verify)
Clinical data
Trade namesDepakote, others
Other namessemisodium valproate, divalproex sodium (USAN US)
License dataUS DailyMedDivalproex_sodium
Identifiers
showIUPAC name
CAS Number76584-70-8 
PubChem CID23663956
DrugBankDBSALT000185 
ChemSpider48337 
UNII644VL95AO6
KEGGD00304 
ChEBICHEBI:4667 
ChEMBLChEMBL2105613 
CompTox Dashboard (EPA)DTXSID6023733 
ECHA InfoCard100.002.525 
Chemical and physical data
FormulaC16H31NaO4
Molar mass310.410 g·mol−1
3D model (JSmol)Interactive image
showSMILES
showInChI

Valproate exists in two main molecular variants: sodium valproate and valproic acid without sodium (often implied by simply valproate). A mixture between these two is termed semisodium valproate. It is unclear whether there is any difference in efficacy between these variants, except from the fact that about 10% more mass of sodium valproate is needed than valproic acid without sodium to compensate for the sodium itself.[114]

Brand names of valproic acid

Branded products include:

Brand names of sodium valproate

Portugal
  • Tablets – Diplexil-R by Bial.
United States
  • Intravenous injection – Depacon by Abbott Laboratories.
  • Syrup – Depakene by Abbott Laboratories. (Note Depakene capsules are valproic acid).
  • Depakote tablets are a mixture of sodium valproate and valproic acid.
  • Tablets – Eliaxim by Bial.
Australia
  • Epilim Crushable Tablets Sanofi[116]
  • Epilim Sugar Free Liquid Sanofi[116]
  • Epilim Syrup Sanofi[116]
  • Epilim Tablets Sanofi[116]
  • Sodium Valproate Sandoz Tablets Sanofi
  • Valpro Tablets Alphapharm
  • Valproate Winthrop Tablets Sanofi
  • Valprease tablets Sigma
New Zealand
  • Epilim by Sanofi-Aventis

All the above formulations are Pharmac-subsidised.[117]

UK
  • Depakote Tablets (as in USA)
  • Tablets – Orlept by Wockhardt and Epilim by Sanofi
  • Oral solution – Orlept Sugar Free by Wockhardt and Epilim by Sanofi
  • Syrup – Epilim by Sanofi-Aventis
  • Intravenous injection – Epilim Intravenous by Sanofi
  • Extended release tablets – Epilim Chrono by Sanofi is a combination of sodium valproate and valproic acid in a 2.3:1 ratio.
  • Enteric-coated tablets – Epilim EC200 by Sanofi is a 200-mg sodium valproate enteric-coated tablet.
UK only
  • Capsules – Episenta prolonged release by Beacon
  • Sachets – Episenta prolonged release by Beacon
  • Intravenous solution for injection – Episenta solution for injection by Beacon
Germany, Switzerland, Norway, Finland, Sweden
  • Tablets – Orfiril by Desitin Pharmaceuticals
  • Intravenous injection – Orfiril IV by Desitin Pharmaceuticals
South Africa
  • Syrup – Convulex by Byk Madaus[118]
  • Tablets – Epilim by Sanofi-synthelabo
Malaysia
  • Tablets – Epilim by Sanofi-Aventis
Romania
  • Companies are SANOFI-AVENTIS FRANCE, GEROT PHARMAZEUTIKA GMBH and DESITIN ARZNEIMITTEL GMBH
  • Types are Syrup, Extended release mini tablets, Gastric resistant coated tablets, Gastric resistant soft capsules, Extended release capsules, Extended release tablets and Extended release coated tablets
Canada
Japan
  • Tablets – Depakene by Kyowa Hakko Kirin
  • Extended release tablets – Depakene-R by Kyowa Hakko Kogyo and Selenica-R by Kowa
  • Syrup – Depakene by Kyowa Hakko Kogyo
Europe

In much of Europe, Dépakine and Depakine Chrono (tablets) are equivalent to Epilim and Epilim Chrono above.

Taiwan
Iran
  • Tablets – Epival 200 (enteric coated tablet) and Epival 500 (extended release tablet) by Iran Najo
  • Slow release tablets – Depakine Chrono by Sanofi Winthrop Industrie (France)
Israel

Depalept and Depalept Chrono (extended release tablets) are equivalent to Epilim and Epilim Chrono above. Manufactured and distributed by Sanofi-Aventis.

India, Russia and CIS countries
  • Valparin Chrono by Torrent Pharmaceuticals India
  • Valprol CR by Intas Pharmaceutical (India)
  • Encorate Chrono by Sun Pharmaceutical (India)
  • Serven Chrono by Leeven APL Biotech (India)

Brand names of valproate semisodium

  • Brazil – Depakote by Abbott Laboratories and Torval CR by Torrent do Brasil
  • Canada – Epival by Abbott Laboratories
  • Mexico – Epival and Epival ER (extended release) by Abbott Laboratories
  • United Kingdom – Depakote (for psychiatric conditions) and Epilim (for epilepsy) by Sanofi-Aventis and generics
  • United States – Depakote and Depakote ER (extended release) by Abbott Laboratories and generics[22]
  • India – Valance and Valance OD by Abbott Healthcare Pvt Ltd, Divalid ER by Linux laboratories Pvt Ltd, Valex ER by Sigmund Promedica, Dicorate by Sun Pharma
  • Germany – Ergenyl Chrono by Sanofi-Aventis and generics
  • Chile – Valcote and Valcote ER by Abbott Laboratories
  • France and other European countries — Depakote
  • Peru – Divalprax by AC Farma Laboratories
  • China – Diprate OD

References

  1. Jump up to:a b c d “Depakene, Stavzor (valproic acid) dosing, indications, interactions, adverse effects, and more”Medscape Reference. WebMD. Archived from the original on 21 February 2014. Retrieved 13 February 2014.
  2. Jump up to:a b c d e f g h i j k l “Valproic Acid”. The American Society of Health-System Pharmacists. Archived from the original on 2017-07-31. Retrieved Oct 23, 2015.
  3. ^ “Valproate banned without the pregnancy prevention programme”GOV.UK. Retrieved 26 April 2018.
  4. ^ Owens MJ, Nemeroff CB (2003). “Pharmacology of valproate”. Psychopharmacol Bull. 37 Suppl 2: 17–24. PMID 14624230.
  5. Jump up to:a b c Ghodke-Puranik Y, Thorn CF, Lamba JK, Leeder JS, Song W, Birnbaum AK, Altman RB, Klein TE (April 2013). “Valproic acid pathway: pharmacokinetics and pharmacodynamics”Pharmacogenet. Genomics23 (4): 236–241. doi:10.1097/FPC.0b013e32835ea0b2PMC 3696515PMID 23407051.
  6. ^ “Valproic acid”DrugBank. University of Alberta. 29 July 2017. Archived from the original on 31 July 2017. Retrieved 30 July2017.
  7. ^ Scott, D.F. (1993). The history of epileptic therapy : an account of how medication was developed (1. publ. ed.). Carnforth u.a.: Parthenon Publ. Group. p. 131. ISBN 9781850703914.
  8. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  9. ^ “The Top 300 of 2021”ClinCalc. Retrieved 18 February 2021.
  10. ^ “Divalproex Sodium – Drug Usage Statistics”ClinCalc. Retrieved 18 February 2021.
  11. ^ Brayfield, Alison (ed.). Martindale: The Complete Drug Reference. London: Pharmaceutical Press. Retrieved March 3,2018.
  12. Jump up to:a b c Rossi, S, ed. (2013). Australian Medicines Handbook(2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN 978-0-9805790-9-3.
  13. ^ Löscher W (2002). “Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy”. CNS Drugs16 (10): 669–694. doi:10.2165/00023210-200216100-00003PMID 12269861S2CID 67999301.
  14. ^ Olsen KB, Taubøll E, Gjerstad L (2007). “Valproate is an effective, well-tolerated drug for treatment of status epilepticus/serial attacks in adults”. Acta Neurol. Scand. Suppl187: 51–4. doi:10.1111/j.1600-0404.2007.00847.xPMID 17419829S2CID 11159645.
  15. ^ Kwan SY (2010). “The role of intravenous valproate in convulsive status epilepticus in the future” (PDF). Acta Neurol Taiwan19(2): 78–81. PMID 20830628.[permanent dead link]
  16. ^ “Valproate Information”. Fda.gov. Archived from the original on 2015-05-03. Retrieved 2015-04-24.
  17. ^ Jochim, Janina; Rifkin-Zybutz, Raphael; Geddes, John; Cipriani, Andrea (7 October 2019). “Valproate for acute mania”Cochrane Database of Systematic Reviews10: CD004052. doi:10.1002/14651858.CD004052.pub2PMC 6797024PMID 31621892.
  18. Jump up to:a b Wang, Y; Xia, J; Helfer, B (2016). “Valproate for schizophrenia”Cochrane Database of Systematic Reviews11: CD004028.pub4. doi:10.1002/14651858.CD004028.pub4PMC 6734130PMID 27884042. Archived from the originalon 2017-07-29. Retrieved 2017-07-27.
  19. ^ Pirritano D, Plastino M, Bosco D, Gallelli L, Siniscalchi A, De Sarro G (2014). “Gambling disorder during dopamine replacement treatment in Parkinson’s disease: a comprehensive review”Biomed Res Int2014: 1–9. doi:10.1155/2014/728038PMC 4119624PMID 25114917.
  20. ^ Connolly B, Fox SH (2014). “Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson’s disease”Neurotherapeutics11 (1): 78–91. doi:10.1007/s13311-013-0238-xPMC 3899484PMID 24288035.
  21. ^ Averbeck BB, O’Sullivan SS, Djamshidian A (2014). “Impulsive and compulsive behaviors in Parkinson’s disease”Annu Rev Clin Psychol10: 553–80. doi:10.1146/annurev-clinpsy-032813-153705PMC 4197852PMID 24313567.
  22. Jump up to:a b c d e f g h i “Depakote- divalproex sodium tablet, delayed release”Archived from the original on 5 March 2016. Retrieved 10 November 2015.
  23. ^ Činčárová L, Zdráhal Z, Fajkus J (2013). “New perspectives of valproic acid in clinical practice”. Expert Opin Investig Drugs22(12): 1535–1547. doi:10.1517/13543784.2013.853037PMID 24160174S2CID 11855893.
  24. Jump up to:a b c d e f g h i j k l m n o “Valpro sodium valproate” (PDF). TGA eBusiness Services. Alphapharm Pty Limited. 16 December 2013. Retrieved 14 February 2014.
  25. ^ “Depakote 250mg Tablets – Summary of Product Characteristics”electronic Medicines Compendium. Sanofi. 28 November 2013. Archived from the original on 1 February 2014. Retrieved 18 January 2014.
  26. ^ Wu S, Legido A, De Luca F (2004). “Effects of valproic acid on longitudinal bone growth”. J Child Neurol19 (1): 26–30. doi:10.1177/088307380401900105011PMID 15032379S2CID 19827846.
  27. ^ Robinson PB, Harvey W, Belal MS (1988). “Inhibition of cartilage growth by the anticonvulsant drugs diphenylhydantoin and sodium valproate”Br J Exp Pathol69 (1): 17–22. PMC 2013195PMID 3126792.
  28. ^ Guo CY, Ronen GM, Atkinson SA (2002). “Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy”. Epilepsia42 (9): 1141–7. doi:10.1046/j.1528-1157.2001.416800.xPMID 11580761S2CID 25499280.
  29. ^ Guo CY, Ronen GM, Atkinson SA (2002). “Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy”. Epilepsia42 (9): 1141–7. doi:10.1046/j.1528-1157.2001.416800.xPMID 11580761S2CID 25499280.
  30. ^ “Could Depakote cause Mydriasis”. eHealthMe.com. 2014-11-18. Archived from the original on 2014-12-05. Retrieved 2015-04-24.
  31. ^ Bilo, Leonilda; Meo, Roberta (October 2008). “Polycystic ovary syndrome in women using valproate: a review”. Gynecological Endocrinology24 (10): 562–70. doi:10.1080/09513590802288259PMID 19012099S2CID 36426338.
  32. ^ Chukwu, J; Delanty, N; Webb, D; Cavalleri, GL (January 2014). “Weight change, genetics and antiepileptic drugs”. Expert Review of Clinical Pharmacology7 (1): 43–51. doi:10.1586/17512433.2014.857599PMID 24308788S2CID 33444886.
  33. ^ New evidence in France of harm from epilepsy drug valproateArchived 2017-04-21 at the Wayback Machine BBC, 2017
  34. ^ Koch S, Göpfert-Geyer I, Jäger-Roman E, et al. (February 1983). “[Anti-epileptic agents during pregnancy. A prospective study on the course of pregnancy, malformations and child development]”. Dtsch. Med. Wochenschr. (in German). 108 (7): 250–7. doi:10.1055/s-2008-1069536PMID 6402356.
  35. ^ Moore SJ, Turnpenny P, Quinn A, et al. (July 2000). “A clinical study of 57 children with fetal anticonvulsant syndromes”J. Med. Genet37 (7): 489–97. doi:10.1136/jmg.37.7.489PMC 1734633PMID 10882750.
  36. ^ Ornoy A (2009). “Valproic acid in pregnancy: how much are we endangering the embryo and fetus?”. Reprod. Toxicol28 (1): 1–10. doi:10.1016/j.reprotox.2009.02.014PMID 19490988.
  37. ^ Kulkarni ML, Zaheeruddin M, Shenoy N, Vani HN (2006). “Fetal valproate syndrome”. Indian J Pediatr73 (10): 937–939. doi:10.1007/bf02859291PMID 17090909S2CID 38371596.
  38. ^ Adab N, Kini U, Vinten J, et al. (November 2004). “The longer term outcome of children born to mothers with epilepsy”J. Neurol. Neurosurg. Psychiatry75 (11): 1575–83. doi:10.1136/jnnp.2003.029132PMC 1738809PMID 15491979This argues that the fetal valproate syndrome constitutes a real clinical entity that includes developmental delay and cognitive impairments, but that some children might exhibit some developmental delay without marked dysmorphism.
  39. ^ Umur AS, Selcuki M, Bursali A, Umur N, Kara B, Vatansever HS, Duransoy YK (2012). “Simultaneous folate intake may prevent adverse effect of valproic acid on neurulating nervous system”. Childs Nerv Syst28 (5): 729–737. doi:10.1007/s00381-011-1673-9PMID 22246336S2CID 20344828.
  40. ^ Cassels, Caroline (December 8, 2006). “NEAD: In Utero Exposure To Valproate Linked to Poor Cognitive Outcomes in Kids”. Medscape. Archived from the original on July 31, 2011. Retrieved 2007-05-23.
  41. ^ Meador KJ, Baker GA, Finnell RH, Kalayjian LA, Liporace JD, Loring DW, Mawer G, Pennell PB, Smith JC, Wolff MC (2006). “In utero antiepileptic drug exposure: fetal death and malformations”Neurology67 (3): 407–412. doi:10.1212/01.wnl.0000227919.81208.b2PMC 1986655PMID 16894099.
  42. ^ Christensen J, Grønborg TK, Sørensen MJ, Schendel D, Parner ET, Pedersen LH, Vestergaard M (2013). “Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism”JAMA309 (16): 1696–1703. doi:10.1001/jama.2013.2270PMC 4511955PMID 23613074.
  43. ^ Rasalam AD, Hailey H, Williams JH, et al. (August 2005). “Characteristics of fetal anticonvulsant syndrome associated autistic disorder”. Dev Med Child Neurol47 (8): 551–5. doi:10.1017/S0012162205001076PMID 16108456.
  44. ^ Autism Society of America: About Autism Archived 2011-01-10 at the Wayback Machine
  45. ^ I.Q. Harmed by Epilepsy Drug in Utero Archived 2015-12-29 at the Wayback Machine By RONI CARYN RABIN, New York Times, April 15, 2009
  46. ^ Meador KJ, Baker GA, Browning N, Clayton-Smith J, Combs-Cantrell DT, Cohen M, Kalayjian LA, Kanner A, Liporace JD, Pennell PB, Privitera M, Loring DW (2009). “Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs”N. Engl. J. Med360 (16): 1597–1605. doi:10.1056/NEJMoa0803531PMC 2737185PMID 19369666.
  47. ^ Valproate Products: Drug Safety Communication – Risk of Impaired Cognitive Development in Children Exposed In Utero (During Pregnancy) Archived 2011-09-02 at the Wayback Machine. FDA. June 2011
  48. ^ Luat, AF (20 September 2007). “Paroxysmal tonic upgaze of childhood with co-existent absence epilepsy”. Epileptic Disorders9(3): 332–6. doi:10.1684/epd.2007.0119 (inactive 31 May 2021). PMID 17884759.
  49. ^ Ouvrier, RA (July 1988). “Benign paroxysmal tonic upgaze of childhood”. Journal of Child Neurology3 (3): 177–80. doi:10.1177/088307388800300305PMID 3209843S2CID 38127378.
  50. ^ Valproate Not To Be Used for Migraine During Pregnancy, FDA Warns Archived 2013-07-09 at the Wayback Machine
  51. ^ “New measures to avoid valproate exposure in pregnancy endorsed”European Medicines Agency. 31 May 2018.
  52. Jump up to:a b c d Bentley, Suzanne (Dec 11, 2013). “Valproic Acid Level”MedscapeArchived from the original on 2015-05-04. Retrieved 2015-06-05.
  53. Jump up to:a b c d “Free Valproic Acid Assay (Reference – 2013.03.006) Notice of Assessment” (PDF). Canadian Agency for Drugs and Technologies in Health (CADTH) with INESSS’s permission. April 2014. Archived from the original (PDF) on 2016-03-03. Retrieved 2015-06-05.
  54. ^ Rissardo, Jamir Pitton; Caprara, Ana Letícia Fornari; Durante, Ícaro (2021). “Valproate-associated Movement Disorder: A Literature Review”Prague Medical Report122 (3): 140–180. doi:10.14712/23362936.2021.14ISSN 1214-6994.
  55. ^ Sztajnkrycer MD (2002). “Valproic acid toxicity: overview and management”. J. Toxicol. Clin. Toxicol40 (6): 789–801. doi:10.1081/CLT-120014645PMID 12475192S2CID 23031095.
  56. ^ Patsalos PN, Berry DJ (2013). “Therapeutic drug monitoring of antiepileptic drugs by use of saliva”. Ther Drug Monit35 (1): 4–29. doi:10.1097/FTD.0b013e31827c11e7PMID 23288091S2CID 15338188.
  57. ^ Thanacoody RH (2009). “Extracorporeal elimination in acute valproic acid poisoning”. Clin Toxicol47 (7): 609–616. doi:10.1080/15563650903167772PMID 19656009S2CID 13592043.
  58. ^ R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 1622–1626.
  59. Jump up to:a b Lheureux PE, Penaloza A, Zahir S, Gris M (2005). “Science review: carnitine in the treatment of valproic acid-induced toxicity – what is the evidence?”Crit Care9 (5): 431–440. doi:10.1186/cc3742PMC 1297603PMID 16277730.
  60. ^ Mock CM, Schwetschenau KH (2012). “Levocarnitine for valproic-acid-induced hyperammonemic encephalopathy”. Am J Health Syst Pharm69 (1): 35–39. doi:10.2146/ajhp110049PMID 22180549.
  61. ^ Matsuoka M, Igisu H (1993). “Comparison of the effects of L-carnitine, D-carnitine and acetyl-L-carnitine on the neurotoxicity of ammonia”. Biochem. Pharmacol46 (1): 159–164. doi:10.1016/0006-2952(93)90360-9PMID 8347126.
  62. ^ Herzog, Andrew; Farina, Erin (June 9, 2005). “Serum Valproate Levels with Oral Contraceptive Use”. Epilepsia46 (6): 970–971. doi:10.1111/j.1528-1167.2005.00605.xPMID 15946343S2CID 7696039.
  63. ^ Kay, Hee Yeon; Greene, Derek L.; Kang, Seungwoo; Kosenko, Anastasia; Hoshi, Naoto (2015-10-01). “M-current preservation contributes to anticonvulsant effects of valproic acid”The Journal of Clinical Investigation125 (10): 3904–3914. doi:10.1172/JCI79727ISSN 0021-9738PMC 4607138PMID 26348896.
  64. ^ Chang P, Walker MC, Williams RS (2014). “Seizure-induced reduction in PIP3 levels contributes to seizure-activity and is rescued by valproic acid”Neurobiol. Dis62: 296–306. doi:10.1016/j.nbd.2013.10.017PMC 3898270PMID 24148856.
  65. ^ Kostrouchová M, Kostrouch Z, Kostrouchová M (2007). “Valproic acid, a molecular lead to multiple regulatory pathways” (PDF). Folia Biol. (Praha)53 (2): 37–49. PMID 17448293. Archived from the original (PDF) on 2014-02-21. Retrieved 2014-02-13.
  66. Jump up to:a b Chiu CT, Wang Z, Hunsberger JG, Chuang DM (2013). “Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder”Pharmacol. Rev65 (1): 105–142. doi:10.1124/pr.111.005512PMC 3565922PMID 23300133.
  67. Jump up to:a b Death AK, McGrath KC, Handelsman DJ (2005). “Valproate is an anti-androgen and anti-progestin” (PDF). Steroids70 (14): 946–53. doi:10.1016/j.steroids.2005.07.003hdl:10453/16875PMID 16165177S2CID 25958985.
  68. Jump up to:a b Wyllie E, Cascino GD, Gidal BE, Goodkin HP (17 February 2012). Wyllie’s Treatment of Epilepsy: Principles and Practice. Lippincott Williams & Wilkins. pp. 288–. ISBN 978-1-4511-5348-4Archived from the original on 6 June 2014.
  69. ^ Uchida, Hiroshi; Maruyama, Tetsuo; Arase, Toru; Ono, Masanori; Nagashima, Takashi; Masuda, Hirotaka; Asada, Hironori; Yoshimura, Yasunori (2005). “Histone acetylation in reproductive organs: Significance of histone deacetylase inhibitors in gene transcription”Reproductive Medicine and Biology4 (2): 115–122. doi:10.1111/j.1447-0578.2005.00101.xISSN 1445-5781PMC 5891791PMID 29662388.
  70. Jump up to:a b Isojärvi, Jouko I T; Taubøll, Erik; Herzog, Andrew G (2005). “Effect of Antiepileptic Drugs on Reproductive Endocrine Function in Individuals with Epilepsy”. CNS Drugs19 (3): 207–223. doi:10.2165/00023210-200519030-00003ISSN 1172-7047PMID 15740176S2CID 9893959.
  71. Jump up to:a b c d e f Haberfeld H, ed. (2021). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. Depakine chrono retard 300 mg Filmtabletten.
  72. ^ Kumar, S.; Wong, H.; Yeung, S. A.; Riggs, K. W.; Abbott, F. S.; Rurak, D. W. (2000). “Disposition of valproic acid in maternal, fetal, and newborn sheep. II: Metabolism and renal elimination”. Drug Metabolism and Disposition: The Biological Fate of Chemicals28(7): 857–864. PMID 10859160.
  73. ^ Schneemann; Young, Lloyd; Koda-Kimble, Mary Anne, eds. (2001). Angewandte Arzneimitteltherapie (in German). Springer. pp. 28–29. ISBN 3540413561.
  74. Jump up to:a b Valproate FDA Professional Drug Information. Accessed 2021-08-06.
  75. Jump up to:a b c d e f g h “Pharmacology”Valproic AcidDrugBank. University of Alberta. 31 August 2017.
  76. ^ Burton BS (1882). “On the propyl derivatives and decomposition products of ethylacetoacetate”. Am. Chem. J3: 385–395.
  77. ^ Meunier H, Carraz G, Neunier Y, Eymard P, Aimard M (1963). “[Pharmacodynamic properties of N-dipropylacetic acid]” [Pharmacodynamic properties of N-dipropylacetic acid]. Thérapie (in French). 18: 435–438. PMID 13935231.
  78. ^ Perucca E (2002). “Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience”. CNS Drugs16 (10): 695–714. doi:10.2165/00023210-200216100-00004PMID 12269862S2CID 803106.
  79. ^ Henry TR (2003). “The history of valproate in clinical neuroscience”. Psychopharmacol Bull. 37 Suppl 2: 5–16. PMID 14624229.
  80. ^ Joint Formulary Committee (2013). British National Formulary (BNF) (65 ed.). London, UK: Pharmaceutical Press. ISBN 978-0-85711-084-8.
  81. ^ Rimmer EM, Richens A (May–June 1985). “An update on sodium valproate”. Pharmacotherapy5 (3): 171–84. doi:10.1002/j.1875-9114.1985.tb03413.xPMID 3927267S2CID 7700266.
  82. ^ Glauser, Tracy A; Cnaan, Avital; Shinnar, Shlomo; Hirtz, Deborah G; Dlugos, Dennis; Masur, David; Clark, Peggy O; Capparelli, Edmund V; Adamson, Peter C (2010). “Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy”New England Journal of Medicine362 (9): 790–9. doi:10.1056/NEJMoa0902014PMC 2924476PMID 20200383.
  83. ^ Jiang, Mei (6 April 2015). “Co-Administration of Valproic Acid and Lamotrigine in the Treatment of Refractory Epilepsy (P1.238)”Neurology84 (14 Supplement): P1.238 – via http://www.neurology.org.
  84. ^ Berendsen, S.; Kroonen, J.; Seute, T.; Snijders, T.; Broekman, M. L. D.; Spliet, W. G. M.; Willems, M.; Artesi, M.; Bours, V.; Robe, P. A. (1 September 2014). “O9.06 * Prognostic Relevance and Oncogenic Correlates of Epilepsy in Glioblastoma Patients”Neuro-Oncology16 (suppl_2): ii21. doi:10.1093/neuonc/nou174.77PMC 4185847.
  85. ^ Vasudev K, Mead A, Macritchie K, Young AH (2012). “Valproate in acute mania: is our practice evidence based?”. Int J Health Care Qual Assur25 (1): 41–52. doi:10.1108/09526861211192395PMID 22455007.
  86. ^ Bond DJ, Lam RW, Yatham LN (2010). “Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis”. J Affect Disord124 (3): 228–334. doi:10.1016/j.jad.2009.11.008PMID 20044142.
  87. ^ Haddad PM, Das A, Ashfaq M, Wieck A (2009). “A review of valproate in psychiatric practice”. Expert Opin Drug Metab Toxicol5(5): 539–51. doi:10.1517/17425250902911455PMID 19409030S2CID 74028228.
  88. ^ Frazee LA, Foraker KC (2008). “Use of intravenous valproic acid for acute migraine”. Ann Pharmacother42 (3): 403–7. doi:10.1345/aph.1K531PMID 18303140S2CID 207263036.
  89. ^ Wang, Yijun; Xia, Jun; Helfer, Bartosz; Li, Chunbo; Leucht, Stefan (2016). “Valproate for schizophrenia”The Cochrane Database of Systematic Reviews11: CD004028. doi:10.1002/14651858.CD004028.pub4ISSN 1469-493XPMC 6734130PMID 27884042.
  90. Jump up to:a b Baillon, Sarah F.; Narayana, Usha; Luxenberg, Jay S.; Clifton, Andrew V. (2018-10-05). “Valproate preparations for agitation in dementia”The Cochrane Database of Systematic Reviews2018(10): CD003945. doi:10.1002/14651858.CD003945.pub4ISSN 1469-493XPMC 6516950PMID 30293233.
  91. ^ Gill D, Derry S, Wiffen PJ, Moore RA (2011). “Valproic acid and sodium valproate for neuropathic pain and fibromyalgia in adults”Cochrane Database Syst Rev (10): CD009183. doi:10.1002/14651858.CD009183.pub2PMC 6540387PMID 21975791.
  92. ^ Aliyev ZN, Aliyev NA (July–August 2008). “Valproate treatment of acute alcohol hallucinosis: a double-blind, placebo-controlled study”. Alcohol Alcohol43 (4): 456–459. doi:10.1093/alcalc/agn043PMID 18495806.
  93. ^ Jacobson PL, Messenheimer JA, Farmer TW (1981). “Treatment of intractable hiccups with valproic acid”. Neurology31 (11): 1458–60. doi:10.1212/WNL.31.11.1458PMID 6796902S2CID 1578958.
  94. ^ Sotaniemi K (1982). “Valproic acid in the treatment of nonepileptic myoclonus”. Arch. Neurol39 (7): 448–9. doi:10.1001/archneur.1982.00510190066025PMID 6808975.
  95. ^ Wheeler SD (July–August 1998). “Significance of migrainous features in cluster headache: divalproex responsiveness”. Headache38 (7): 547–51. doi:10.1046/j.1526-4610.1998.3807547.xPMID 15613172S2CID 27948702.
  96. ^ Siemes H, Spohr HL, Michael T, Nau H (September–October 1988). “Therapy of infantile spasms with valproate: results of a prospective study”. Epilepsia29 (5): 553–60. doi:10.1111/j.1528-1157.1988.tb03760.xPMID 2842127S2CID 23789333.
  97. ^ Smith SM (2005). “Valproic acid and HIV-1 latency: beyond the sound bite” (PDF). Retrovirology2 (1): 56. doi:10.1186/1742-4690-2-56PMC 1242254PMID 16168066. Archived from the original (PDF) on 2015-09-24. Retrieved 2014-02-13.
  98. ^ Routy JP, Tremblay CL, Angel JB, Trottier B, Rouleau D, Baril JG, Harris M, Trottier S, Singer J, Chomont N, Sékaly RP, Boulassel MR (2012). “Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study”. HIV Med13 (5): 291–6. doi:10.1111/j.1468-1293.2011.00975.xPMID 22276680S2CID 27571864.
  99. ^ Archin NM, Cheema M, Parker D, Wiegand A, Bosch RJ, Coffin JM, Eron J, Cohen M, Margolis DM (2010). “Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection”PLOS ONE5 (2): e9390. Bibcode:2010PLoSO…5.9390Adoi:10.1371/journal.pone.0009390PMC 2826423PMID 20186346.
  100. Jump up to:a b Hardy JR, Rees EA, Gwilliam B, Ling J, Broadley K, A’Hern R (2001). “A phase II study to establish the efficacy and toxicity of sodium valproate in patients with cancer-related neuropathic pain” (PDF). J Pain Symptom Manage21 (3): 204–9. doi:10.1016/S0885-3924(00)00266-9PMID 11239739.[permanent dead link]
  101. ^ Candelaria M, Herrera A, Labardini J, González-Fierro A, Trejo-Becerril C, Taja-Chayeb L, Pérez-Cárdenas E, de la Cruz-Hernández E, Arias-Bofill D, Vidal S, Cervera E, Dueñas-Gonzalez A (2011). “Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial”. Ann. Hematol90 (4): 379–387. doi:10.1007/s00277-010-1090-2PMID 20922525S2CID 13437134.
  102. ^ Bug G, Ritter M, Wassmann B, Schoch C, Heinzel T, Schwarz K, Romanski A, Kramer OH, Kampfmann M, Hoelzer D, Neubauer A, Ruthardt M, Ottmann OG (2005). “Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia”. Cancer104 (12): 2717–2725. doi:10.1002/cncr.21589PMID 16294345S2CID 1802132.
  103. ^ Kuendgen A, Schmid M, Schlenk R, Knipp S, Hildebrandt B, Steidl C, Germing U, Haas R, Dohner H, Gattermann N (2006). “The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia”. Cancer106 (1): 112–119. doi:10.1002/cncr.21552PMID 16323176S2CID 43747497.
  104. ^ Fredly H, Gjertsen BT, Bruserud O (2013). “Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents” (PDF). Clin Epigenetics5 (1): 12. doi:10.1186/1868-7083-5-12PMC 3733883PMID 23898968. Archived from the original (PDF) on 2014-02-21. Retrieved 2014-02-13.
  105. ^ Coronel J, Cetina L, Pacheco I, Trejo-Becerril C, González-Fierro A, de la Cruz-Hernandez E, Perez-Cardenas E, Taja-Chayeb L, Arias-Bofill D, Candelaria M, Vidal S, Dueñas-González A (2011). “A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results”. Med. Oncol. 28 Suppl 1: S540–6. doi:10.1007/s12032-010-9700-3PMID 20931299S2CID 207372333.
  106. ^ Rocca A, Minucci S, Tosti G, Croci D, Contegno F, Ballarini M, Nolè F, Munzone E, Salmaggi A, Goldhirsch A, Pelicci PG, Testori A (2009). “A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma”Br. J. Cancer100 (1): 28–36. doi:10.1038/sj.bjc.6604817PMC 2634690PMID 19127265.
  107. ^ Munster P, Marchion D, Bicaku E, Lacevic M, Kim J, Centeno B, Daud A, Neuger A, Minton S, Sullivan D (2009). “Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC” (PDF). Clin. Cancer Res15 (7): 2488–96. doi:10.1158/1078-0432.CCR-08-1930PMID 19318486S2CID 3230087.
  108. ^ Hicks CW, Pandya MM, Itin I, Fernandez HH (2011). “Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson’s disease”. Parkinsonism Relat. Disord17 (5): 379–81. doi:10.1016/j.parkreldis.2011.03.003PMID 21459656.
  109. ^ Sriram A, Ward HE, Hassan A, Iyer S, Foote KD, Rodriguez RL, McFarland NR, Okun MS (2013). “Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson’s disease”. J. Neurol260 (2): 521–7. doi:10.1007/s00415-012-6669-1PMID 23007193S2CID 21544457.
  110. ^ Aizenman, N. C. (7 May 2012). “Abbott Laboratories to pay $1.6 billion over illegal marketing of Depakote”Washington Post. Retrieved 27 June 2018.
  111. ^ Schmidt, Michael; Thomas, Katie (8 May 2012). “Abbott settles marketing lawsuit”New York Times. Retrieved 27 June 2018.
  112. ^ Gervain J, Vines BW, Chen LM, Seo RJ, Hensch TK, Werker JF, Young AH (2013). “Valproate reopens critical-period learning of absolute pitch”Frontiers in Systems Neuroscience7: 102. doi:10.3389/fnsys.2013.00102PMC 3848041PMID 24348349.
  113. ^ Thomson, Helen. “Learning drugs reawaken grown-up brain’s inner child”New Scientist. New Scientist Ltd. Retrieved 8 May2021.
  114. ^ David Taylor; Carol Paton; Shitij Kapur (2009). The Maudsley Prescribing Guidelines, Tenth Edition (10, revised ed.). CRC Press. p. 124. ISBN 9780203092835.
  115. ^ “Depakene- valproic acid capsule, liquid filled”DailyMed. 19 September 2019. Retrieved 14 April 2020.
  116. Jump up to:a b c d “Australian product information epilim (sodium valproate) crushable tablets, enteric-coated tablets, syrup, liquid” (PDF). TGA eBS. 15 April 2020. Retrieved 15 April 2020.
  117. ^ “Sodium valproate — Pharmaceutical Schedule”. Pharmaceutical Management Agency. Archived from the originalon 4 March 2016. Retrieved 22 June 2014.
  118. ^ South African Electronic Package Inserts: Convulex

External links

Clinical data
Trade namesDepakote, Epilim, Convulex, others
Other namesValproic acid; Sodium valproate (sodium); Valproate semisodium (semisodium); 2-Propylvaleric acid
AHFS/Drugs.comMonograph
MedlinePlusa682412
License dataUS DailyMedValproic_acidUS FDAValproic%20acid
Pregnancy
category
AU: D
Routes of
administration
By mouthintravenous
ATC codeN03AG01 (WHO)
Legal status
Legal statusAU: S4 (Prescription only)CA℞-onlyUK: POM (Prescription only)US: ℞-only
Pharmacokinetic data
BioavailabilityRapid absorption
Protein binding80–90%[1]
MetabolismLiverglucuronide conjugation 30–50%, mitochondrial β-oxidation over 40%
Elimination half-life9–16 hours[1]
ExcretionUrine (30–50%)[1]
Identifiers
showIUPAC name
CAS Number99-66-1 
PubChem CID3121
IUPHAR/BPS7009
DrugBankDB00313 
ChemSpider3009 
UNII614OI1Z5WI
KEGGD00399 
ChEBICHEBI:39867 
ChEMBLChEMBL109 
NIAID ChemDB057177
CompTox Dashboard (EPA)DTXSID6023733 
ECHA InfoCard100.002.525 
Chemical and physical data
FormulaC8H16O2
Molar mass144.214 g·mol−1
3D model (JSmol)Interactive image
showSMILES
showInChI
  (verify)

Patent 

Publication numberPriority datePublication dateAssigneeTitleCA1144558A *1979-10-221983-04-12Francis E. FischerProcess for making sodium hydrogen divalproateUS4988731A *1979-08-201991-01-29Abbott LaboratoriesSodium hydrogen divalproate oligomerUS5212326A *1979-08-201993-05-18Abbott LaboratoriesSodium hydrogen divalproate oligomerWO2001032595A1 *1999-11-022001-05-10Cilag AgMethod for producing compounds of the valproinic acidUS20030018215A1 *2001-06-292003-01-23Procos S.P.A.Process for the preparation of sodium divalproatePublication numberPriority datePublication dateAssigneeTitleUS20110040122A1 *2009-08-112011-02-17Sci Pharmtech, Inc.Method for preparing metal salt of valproic acidCN102942467A *2012-10-172013-02-27山东方明药业集团股份有限公司Preparation method of divalproex sodiumCN103183600A *2011-12-302013-07-03北大方正集团有限公司Method for preparing divalproex sodium

////// divalproex, Anticonvulsant,  Antimigraine, Antimanic, valproic acid, sodium valproate

CCCC(CCC)C(O)=O

NEW DRUG APPROVALS

ONE TIME

$10.00


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

DR ANTHONY CRASTO

Follow New Drug Approvals on WordPress.com

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 2,674 other followers

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with GLENMARK LIFE SCIENCES LTD, Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 30 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri, Dr T.V. Radhakrishnan and Dr B. K. Kulkarni, etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him Open superstar worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international, etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 30 PLUS year tenure till date June 2021, Around 35 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 9 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 90 Lakh plus views on dozen plus blogs, 233 countries, 7 continents, He makes himself available to all, contact him on +91 9323115463, email amcrasto@gmail.com, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 33 lakh plus views on New Drug Approvals Blog in 233 countries......https://newdrugapprovals.wordpress.com/ , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc

Personal Links

View Full Profile →

TWITTER

bloglovin

Follow my blog with Bloglovin The title of your home page You could put your verification ID in a comment Or, in its own meta tag Or, as one of your keywords Your content is here. The verification ID will NOT be detected if you put it here.
%d bloggers like this: